You are here

Takeda

Takeda snares approval for all-comer gastric cancer drug

Takeda snares approval for all-comer gastric cancer drug

Medical Marketing and Media

colorectal cancer

Flag link:

Takeda Wins First FDA Approval for Ultra-Rare Blood Clotting Disease

Takeda Wins First FDA Approval for Ultra-Rare Blood Clotting Disease

BioSpace

cogenital thrombocytopenic purpura

Flag link:

Takeda Wins FDA Approval for Fruquintinib in Certain Colorectal Cancer Patients

Takeda Wins FDA Approval for Fruquintinib in Certain Colorectal Cancer Patients

BioSpace

colorectal cancer

Flag link:

Tricks and Treats as Biopharma’s Q3 Earnings Season Gets Underway

Tricks and Treats as Biopharma’s Q3 Earnings Season Gets Underway

BioSpace

Bristol Myers Squibb

Flag link:

Novartis claims ex-staffer jumped to Takeda with 'thousands' of sensitive files

Novartis claims ex-staffer jumped to Takeda with 'thousands' of sensitive files

Fierce Pharma

Flag link:

Takeda Reports $770M Write-Down, Cuts Profit Forecast by 71% for FY2023

Takeda Reports $770M Write-Down, Cuts Profit Forecast by 71% for FY2023

BioSpace

Flag link:

Takeda’s stem cell treatment Alofisel flunks phase 3 trial in Crohn's complication

Takeda’s stem cell treatment Alofisel flunks phase 3 trial in Crohn's complication

Fierce Pharma

Crohn's Disease

clinical trials

Flag link:

Takeda ponies up €130M to settle tax linked to distant AbbVie-Shire breakup fee

Takeda ponies up €130M to settle tax linked to distant AbbVie-Shire breakup fee

Fierce Pharma

Flag link:

Takeda to Withdraw Oncology Drug Exkivity from U.S. Market

Takeda to Withdraw Oncology Drug Exkivity from U.S. Market

Managed Healthcare Executive

clinical trials

non-small cell lung cancer

Flag link:

Path for BrainStorm ALS Treatment Remains Rocky, Hope for Others on Horizon

Path for BrainStorm ALS Treatment Remains Rocky, Hope for Others on Horizon

BioSpace

BrainStorm Cell Therapeutics

Seelos Therapeutics

Flag link:

Takeda’s Entyvio receives FDA approval for subcutaneous administration

Takeda’s Entyvio receives FDA approval for subcutaneous administration

Pharmaceutical Technology

ulcerative colitis

Flag link:

AcuraStem and Takeda Partner to Revolutionize ALS Treatment

AcuraStem and Takeda Partner to Revolutionize ALS Treatment

Best Stocks

Flag link:

Takeda settles antitrust lawsuit over gout drug Colcrys after trial kicked off

Takeda settles antitrust lawsuit over gout drug Colcrys after trial kicked off

Fierce Pharma

Flag link:

Roche scores—again—in hemophilia drug patent case against Takeda

Roche scores—again—in hemophilia drug patent case against Takeda

Fierce Pharma

Flag link:

AbbVie in line for hefty payout after Takeda breached supply contract on Lupron

AbbVie in line for hefty payout after Takeda breached supply contract on Lupron

Fierce Pharma

Flag link:

Fresh off $4B deal, Nimbus gears up for ‘third chapter’ with new fundraise

Fresh off $4B deal, Nimbus gears up for ‘third chapter’ with new fundraise

BioPharma Dive

Nimbus Therapeutics

Flag link:

Takeda, Denali drop Alzheimer's asset after phase 1 peak reveals 'narrow therapeutic window'

Takeda, Denali drop Alzheimer's asset after phase 1 peak reveals 'narrow therapeutic window'

Fierce Biotech

Denali Therapeutics

Alzheimer's disease

clinical trials

Flag link:

FDA Clears Taiho’s Lonsurf in Metastatic Colorectal Cancer Ahead of Takeda, Hutchmed

FDA Clears Taiho’s Lonsurf in Metastatic Colorectal Cancer Ahead of Takeda, Hutchmed

BioSpace

colorectal cancer

Flag link:

Filings signal: Despite Covid losses, pharma earnings are promising

Filings signal: Despite Covid losses, pharma earnings are promising

Clinical Trials Arena

Flag link:

Pages